CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Peginterferon Lambda-1aWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1638 pregnant women with laboratory-confirmed 2019-n-CoV Wiki 0.71
drug1016 Placebo Wiki 0.08

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.13
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase 2 Randomized, Single Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.

NCT04331899 COVID-19 Drug: Peginterferon Lambda-1a Other: Placebo

Primary Outcomes

Description: Time to first of two consecutive negative respiratory secretions obtained by nasopharyngeal and/or oropharyngeal and/or salivary swabs tests for SARS-CoV-2 by qRT-PCR.

Measure: Duration of Viral shedding of SARS-CoV-2 by qRT-PCR

Time: 28 days


No related HPO nodes (Using clinical trials)